Transdermal Or Percutaneous Patents (Class 424/449)
-
Patent number: 8420117Abstract: A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.Type: GrantFiled: July 6, 2010Date of Patent: April 16, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Hideharu Chono, Toshiro Yamaguchi, Hisakazu Kurita, Tetsuro Tateishi, Naruhito Higo
-
Patent number: 8409610Abstract: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.Type: GrantFiled: September 12, 2011Date of Patent: April 2, 2013Assignee: Coloplast A/SInventors: Gitte Juel Friis, Truels Sterm Larsen
-
Patent number: 8409609Abstract: A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.Type: GrantFiled: June 5, 2006Date of Patent: April 2, 2013Assignee: Nitto Denko CorporationInventors: Keigo Inosaka, Junichi Sekiya, Akio Takada, Toshinobu Tsuda
-
Patent number: 8404273Abstract: A variety of article and systems including wound care systems, methods for making the wound care systems, bactericidal, and methods for treating wounds using these systems are disclosed. The wound care systems may include a first material comprising one or more fibers or porous media. The one or more fibers or porous media may be coated with a second material that is capable of inhibiting the growth of bacteria and killing the bacteria to render the wound care system sterile, increasing the absorbency of the first material, or both upon exposure to light. The first material may be cotton, or any suitable fibrous material, the second material may be TiO2, and the light may be UV or visible light. A variety of methods including ALD may be used to coat the first material.Type: GrantFiled: April 23, 2010Date of Patent: March 26, 2013Assignee: Old Dominion University Research FoundationInventors: Helmut Baumgart, Diefeng Gu
-
Patent number: 8389000Abstract: Disclosed is an adhesive skin patch having an SIS block copolymer as an adhesive component, which has an improved handling property and can reduce irritation to a user. The adhesive skin patch comprises a flexible substrate and an adhesive layer laminated on the substrate, wherein the adhesive layer comprises a styrene-isoprene-styrene block copolymer. In the adhesive skin patch, the tan ? value of the adhesive agent as determined by measuring a dynamic viscoelasticity at 32° C. satisfies a requirement represented by the following formula 1 at at least one frequency laying between 0.04 to 0.25 Hz. 0.25x+0.05?y?0.25x+0.10 (formula 1) [wherein x represents a frequency (Hz); and y represents a tan ? value.Type: GrantFiled: November 29, 2007Date of Patent: March 5, 2013Assignee: Nipro Patch Co., Ltd.Inventors: Naohisa Kawamura, Takashi Saitoh, Junko Tsuchiya
-
Patent number: 8386030Abstract: An iontophoresis device including an active electrode assembly or a counter electrode assembly with a polarizable electrode containing any one of a conductive material having a capacitance per unit weight of 1 F/g or greater, a conductive material having a specific surface area of 10 m2/g or greater, and activated carbon is disclosed. The generation of gas or ions due to an electrode reaction occurring in an electrode assembly may be reduced or prevented. In addition, the alteration of an active agent due to a chemical reaction upon energization may be reduced or prevented.Type: GrantFiled: August 8, 2006Date of Patent: February 26, 2013Assignee: TTI Ellebeau, Inc.Inventors: Kiyoshi Kanamura, Nobuharu Kosiba, Mizuo Nakayama, Takehiko Matsumura, Hidero Akiyama, Akihiko Matsumura
-
Patent number: 8383149Abstract: A polyacrylate formulation suitable for delivery of drug through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.Type: GrantFiled: September 22, 2006Date of Patent: February 26, 2013Assignee: ALZA CorporationInventors: Jay Audett, Jianye Wen, Eli J. Goldman, Robert M. Gale, Allison Luciano, Paul B. Foreman, Eric N. Silverberg
-
Patent number: 8377016Abstract: A tissue treatment apparatus and method are provided for treating tissue by the application of the time-varying sub-atmospheric pressure. The apparatus includes a cover adapted to cover a wound and adapted to maintain sub-atmospheric pressure the site of the wound. The apparatus further includes a source of suction configured to generate a time-varying sub-atmospheric pressure having a periodic waveform comprising a gradual change in pressure. The suction source cooperates with the cover to supply the time-varying sub-atmospheric pressure under the cover to the wound. The time-varying sub-atmospheric pressure may vary between a first pressure value below the inherent tissue tension of the wound tissue and a second pressure value above the inherent tissue tension of the wound tissue.Type: GrantFiled: January 10, 2007Date of Patent: February 19, 2013Assignee: Wake Forest University Health SciencesInventors: Louis O. Argenta, Michael J. Morykwas, Lawrence X. Webb
-
Patent number: 8377476Abstract: Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30.Type: GrantFiled: March 24, 2009Date of Patent: February 19, 2013Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takashi Kamakura, Takefumi Hoshikawa, Yukiko Inamoto, Kayo Tanigawa
-
Patent number: 8372806Abstract: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises a drug (5a), wherein the drug effects at least one of the biological regulation of at least one oocyte containing follicle, stimulation of follicle growth, induction of ovulation, promotion of gestational status, maintenance of conceptus, maintenance of pregnancy.Type: GrantFiled: October 6, 2006Date of Patent: February 12, 2013Assignee: Pantec Biosolutions AGInventors: Christof Böhler, Thomas Bragagna, Reinhard Braun, Werner Braun, Herbert Zech
-
Patent number: 8366600Abstract: A patch and compositions for iontophoresis of triptan compounds are described.Type: GrantFiled: June 19, 2008Date of Patent: February 5, 2013Assignee: NuPathe Inc.Inventors: Terri B. Sebree, Michael Horstmann, Mohammad Sameti
-
Patent number: 8361022Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.Type: GrantFiled: July 1, 2009Date of Patent: January 29, 2013Assignee: Alza CorporationInventors: Mahmoud Ameri, Michel J. N. Cormier, Yuh-Fun Maa, Peter E. Daddona, Marika Kamberl
-
Patent number: 8361493Abstract: The patch according to an embodiment of the present invention includes: a support; and a pressure-sensitive adhesive layer on at least one surface of the support, wherein: the pressure-sensitive adhesive layer contains an acrylic copolymer obtained by copolymerizing monomer components containing (a) at least one kind of a monomer of a (meth)acrylic acid alkyl ester and (b) at least one kind of a monomer of an N-hydroxyalkyl(meth)acrylamide; a content of the (meth)acrylic acid alkyl ester monomer (a) with respect to a total amount of the monomer components is 50 wt % to 90 wt % and a content of the N-hydroxyalkyl(meth)acrylamide monomer (b) with respect to the total amount is 1 wt % to 20 wt %; and the monomer components are substantially free of a monomer having a carboxyl group.Type: GrantFiled: November 12, 2010Date of Patent: January 29, 2013Assignee: Nitto Denko CorporationInventors: Jun Ishikura, Raito Funayama, Yu Tachikawa, Junichi Sekiya, Tsuyoshi Kasahara, Ryo Hashino, Satoshi Ameyama, Hidetoshi Kuroda
-
Patent number: 8357393Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: GrantFiled: December 7, 2004Date of Patent: January 22, 2013Assignee: Acrux DDS Pty Ltd.Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Taci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Patent number: 8357129Abstract: Skin rejuvenation system and method in which a pure plant collagen carrier is saturated with a solution of collagen, allantoin, amino acid, propanediol, glycerin, algae, plant DNA living cells, epidermal growth factor, Vitamin E, hyaluronic acid, rose essential, water, and peptide, and the saturated carrier is applied to the skin to be rejuvenated.Type: GrantFiled: November 10, 2010Date of Patent: January 22, 2013Assignee: Physicans Products, Inc.Inventors: Janet R. Graham, Douglas A. Ginter
-
Patent number: 8349358Abstract: A transdermal analgesic applicator configured to provide a visual signal subsequent sufficient absorption of an analgesic compound ensuing the transdermal analgesic applicator being applied to the skin of a patient. The transdermal analgesic applicator includes a first layer that is impermeable and has integrally formed therewith on at least a portion thereof a plurality of microcapsules containing a thermochromic dye mixture. The first layer having the portion of microcapsules presents a first color at ambient room temperature and a second color at temperature greater than the first temperature as a result of being placed on the skin of a patient. A second layer containing an analgesic compound is secured to the first layer. The first layer changes from the first color to the second color subsequent the first layer changing from the first temperature to the second temperature, which the rate of temperature change is approximately equivalent to the absorption rate of the analgesic compound.Type: GrantFiled: April 15, 2010Date of Patent: January 8, 2013Inventor: Emily Vann McBride
-
Patent number: 8349357Abstract: The present invention provides an adhesive patch comprising a support, an adhesive layer on at least one surface of the support, and a release liner on a surface of the adhesive layer opposite from the support, wherein (a) the lateral end of the adhesive layer is exposed, (b) in at least one lateral end, the lateral end of the adhesive layer is located toward the central part side of the adhesive patch from the lateral end of the support, and (c) when placed horizontally with the release liner facing down, a distance A between the upper end of the support and the lower end of the release liner at said lateral end of the adhesive patch is greater than a thickness B of the central part of the adhesive patch.Type: GrantFiled: September 1, 2011Date of Patent: January 8, 2013Assignee: Nitto Denko CorporationInventors: Jun Harima, Masakatsu Konno, Ryo Hashino, Akira Numata
-
Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systems
Patent number: 8343538Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.Type: GrantFiled: October 7, 2005Date of Patent: January 1, 2013Assignee: Noven Pharmaceuticals, Inc.Inventors: David Kanios, Rod Hartwig -
Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
Patent number: 8337884Abstract: A transdermal composition is disclosed which contains a blend of one or more polymers, one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures. The composition is substantially free of water and liquids which have a normal boiling point (a) optionally below processing temperatures and (b) greater than or equal to the temperature of the low molecular weight drugs. The composition does not suffer from the substantial loss of the lower molecular weight drug during production of the transdermal system. A transdermal composition is also disclosed which has one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures, and a polymer matrix including one or more high shear resistant polymers. The high shear resistant polymer(s) reduce the plasticizing effect of the low molecular weight drug, and has sufficient tack and shear for application to a human being.Type: GrantFiled: March 16, 2011Date of Patent: December 25, 2012Assignee: Noven Pharmaceuticals, Inc.Inventors: Juan Mantelle, David Houze -
Patent number: 8337883Abstract: Disclosed are bupivacaine transdermal delivery systems, and related methods.Type: GrantFiled: October 29, 2007Date of Patent: December 25, 2012Assignee: Durect CorporationInventors: Su Il Yum, Sung Yun Kwon, Xiaoping Song, James E. Brown
-
Patent number: 8332028Abstract: This invention provides new and novel devices and methods for administering lithium (Li) ions to a mammalian subject, especially delivery of the lithium (Li) ions to a body component for example across a body or tissue surface such as skin or a mucosal membrane, or for the delivery of the lithium ions directly to bodily fluids in a controllable and reproducible manner. In certain embodiments the device comprises a donor electrode that is a donor of the lithium ions; a protective architecture that is ionically conductive to the lithium ions, configured for application to a skin surface and positioned to isolate said donor electrode from the skin surface; and a counter electrode configured for application to the skin surface, where said counter electrode is operably coupled to said donor electrode.Type: GrantFiled: November 28, 2007Date of Patent: December 11, 2012Assignee: PolyPlus Battery CompanyInventors: Steven J. Visco, Yevgeniy S. Nimon, Bruce Katz
-
Patent number: 8329212Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.Type: GrantFiled: November 19, 2009Date of Patent: December 11, 2012Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris
-
Patent number: 8323684Abstract: The invention relates to a TTS with backing layers that guarantee a high wear comfort and that facilitate application in regions of the human body that are subject to great mechanical loads, especially the large joints of the extremities. The inventive backing layers overcome the disadvantages with respect to reduced absorption of the active substance by the skin that are typically associated with such backing layers. The inventive systems are preferably used for the local of systemic administration of anti-inflammatory and pain-relieving active substances.Type: GrantFiled: May 15, 2001Date of Patent: December 4, 2012Assignee: LTS Lohmann Therapie-Systeme AGInventors: Stefan Bracht, Christoph Schmitz
-
Patent number: 8309119Abstract: The present invention aims at providing an adhesive preparation wherein a drug is sufficiently dissolved in an adhesive layer and is not easily separated from the adhesive layer even during preservation of the adhesive preparation. The present invention provides an adhesive preparation having an adhesive layer on at least one surface of a support, wherein the adhesive layer comprises a first synthetic rubber having a viscosity average molecular weight of 1,600,000-6,500,000, a drug, an organic liquid component and a tackifier. The present invention further provides the aforementioned adhesive preparation, wherein the organic liquid component is contained in the adhesive layer in a proportion of 20 wt % or above relative to the total weight of the adhesive layer.Type: GrantFiled: February 27, 2008Date of Patent: November 13, 2012Assignee: Nitto Denko CorporationInventors: Masato Nishimura, Sachiko Terashi, Shiro Satoda, Keigo Inosaka, Kensuke Matsuoka
-
Patent number: 8309120Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.Type: GrantFiled: October 4, 2006Date of Patent: November 13, 2012Assignee: LTS Lohmann Therapie-Systeme AGInventors: Andreas Koch, Christoph Schmitz, Rolf Pracht, Mohammad Sameti
-
Patent number: 8298572Abstract: In the adhesive pharmaceutical preparation of the invention containing bisoprolol, a pressure-sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer contains a branched monoalcohol having from 12 to 28 carbon atoms, a free base of bisoprolol and a polyisobutylene pressure-sensitive adhesive. Accordingly, compatibility of the polyisobutylene pressure-sensitive adhesive with the free base of bisoprolol can be specifically increased. As a result, not only it becomes possible to increase blending amount of the free base of bisoprolol but also bleed of the free base of bisoprolol from the pressure-sensitive adhesive layer can be suppressed and, what is more, the pressure-sensitive adhesion characteristics sufficient from the practical point of view can be obtained.Type: GrantFiled: December 13, 2006Date of Patent: October 30, 2012Assignees: Nitto Denko Corporation, Toa Eiyo Ltd.Inventors: Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa
-
Patent number: 8295922Abstract: An iontophoresis device may be capable of preventing or reducing the generation of gas, or the production of undesirable ions, due to an electrode reaction occurring in an electrode assembly; or the alteration of an active agent due to a chemical reaction upon energization. A doping layer made of a substance such as a conductive polymer that effects an electrochemical reaction due to the doping or de-doping of an ion, may be formed in an electrode in an active electrode assembly or counter electrode assembly of an iontophoresis device.Type: GrantFiled: August 7, 2006Date of Patent: October 23, 2012Assignee: TTI ellebeau, Inc.Inventors: Kiyoshi Kanamura, Takehiko Matsumura, Mizuo Nakayama, Hidero Akiyama, Akihiko Matsumura
-
Patent number: 8295924Abstract: A transdermal system for the delivery of an anesthetic or other active therapeutic agent directly to a selected site of injured skin tissue by iontophoresis is disclosed, which utilizes a transdermal skin-worn patch including a donor electrode chamber containing a donor electrode and an amount of an active agent in a form suitable for transdermal delivery in electrical communication with the donor electrode and a return electrode. The patch also contains a source of electric current connected in a circuit with the donor and return electrode, a current regulating device is optionally provided in the circuit for controlling the electrical output of the patch and at least the donor electrode chamber includes a provision for absorbing a quantity of fluid associated with weepage from adjacent injured skin tissue.Type: GrantFiled: January 20, 2011Date of Patent: October 23, 2012Assignee: Teikoku Pharma USA, Inc.Inventors: Carter R. Anderson, Russell L. Morris, Robert Cohen
-
Patent number: 8287899Abstract: The invention relates to a patch for cutaneous application of a substance, the patch comprising a substance designed to penetrate the epidermis, means for placing the substance in contact with the skin and a peelable cutaneous exfoliation film enabling exfoliation of the skin, after placing the patch, at the level of the contact zone between said substance and the skin.Type: GrantFiled: February 15, 2008Date of Patent: October 16, 2012Assignee: DBV TechnologiesInventor: Bertrand Dupont
-
Patent number: 8277838Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, providing drug having differing crystal sizes as well as drug which is solublized in the pressure-sensitive adhesive composition controls the rate of drug delivery from the pressure-sensitive adhesive composition.Type: GrantFiled: December 28, 2010Date of Patent: October 2, 2012Assignee: Noven Pharmaceuticals, Inc.Inventor: Viet Nguyen
-
Patent number: 8273370Abstract: An adhesive patch has a support and an adhesive layer formed on at least one surface of the support. The adhesive patch has a peripheral part and a central part 21. The adhesive layer has voids localized in the peripheral part, with the adhesive layer in the central part being substantially free of voids. The peripheral part preferably contains voids at 2.0-100 voids/mm3 on average. Since time-course changes of adhesive layer components such as additives are reduced, the adhesive patch is highly resistant to detachment from the skin, the components do not easily protrude from the edge of the adhesive patch during preservation in a package, adhesion to the inner surface of the package is suppressed, the adhesive patch can be easily removed from the package and edge lifting by cold flow is suppressed during adhesion to the skin.Type: GrantFiled: August 27, 2009Date of Patent: September 25, 2012Assignee: Nitto Denko CorporationInventors: Jun Harima, Masakatsu Konno, Ryo Hashino, Akira Numata
-
Patent number: 8269059Abstract: A protective device having a substantially rigid casing for placement on a patient's skin, wherein the casing has a hollow interior facing the patient's skin and a lip. The casing can be spanned across its hollow interior by a membrane. The casing can have a first adhesive seal attached to a bottom surface of the lip of the casing, and a second adhesive seal attached to the top surface of the lip of the casing.Type: GrantFiled: August 2, 2011Date of Patent: September 18, 2012Assignee: Venetec International, Inc.Inventors: Clifford A. Wright, Gene Stewart
-
Patent number: 8268346Abstract: The present invention relates generally to methods for treating hot flashes by administering formulations for transdermal or transmucosal administration of estrogen. The formulations of the invention are effective at treating hot flashes at surprisingly low daily doses, preferably the lowest effective dose of estrogen to treat hot flashes, e.g., about 0.45 to about 0.6 mg of estrogen per day. The amount of estrogen which is administered produces an estimated nominal daily estrogen dose in a subject undergoing treatment of from about 10 to about 15 micrograms, and a serum estradiol level of between about 25 pg/ml to about 50 pg/ml. The preferred formulations are substantially free of malodorous, and irritation causing long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.Type: GrantFiled: April 19, 2007Date of Patent: September 18, 2012Assignee: Antares Pharma IPL AGInventors: Stephen M. Simes, Leah M. Lehman
-
Publication number: 20120225112Abstract: The method and apparatus for the administration of alcohol to a person provides an alcohol “patch” in the form of an adhesive patch or bandage-like structure bearing a quantity of alcohol for transdermal delivery to the user. Permeation enhancers, either chemical or structural, may be included for increased efficacy of delivery of the alcohol to the user. The alcohol to be delivered via the inventive apparatus may be plain ethyl alcohol (ethanol) of any suitable concentration or proof. Alternatively, the alcohol may be in the form of various distilled or undistilled spirits.Type: ApplicationFiled: March 5, 2012Publication date: September 6, 2012Inventor: Mark Stephen Saia
-
Patent number: 8252320Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.Type: GrantFiled: July 31, 2007Date of Patent: August 28, 2012Assignee: Durect CorporationInventors: Su Il Yum, Felix Theeuwes
-
Patent number: 8252319Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.Type: GrantFiled: July 31, 2007Date of Patent: August 28, 2012Assignee: Durect CorporationInventors: Su Il Yum, Felix Theeuwes
-
Patent number: 8252321Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.Type: GrantFiled: October 31, 2007Date of Patent: August 28, 2012Assignee: Chrono Therapeutics, Inc.Inventors: Guy Dipierro, Steven A. Giannos
-
Patent number: 8246981Abstract: Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.Type: GrantFiled: November 10, 2006Date of Patent: August 21, 2012Assignee: Abeille Pharamaceuticals, Inc.Inventors: Kalpana J Patel, Suresh Borsadia
-
Patent number: 8246976Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, providing drug having differing crystal sizes as well as drug which is solublized in the pressure-sensitive adhesive composition controls the rate of drug delivery from the pressure-sensitive adhesive composition.Type: GrantFiled: October 7, 2005Date of Patent: August 21, 2012Assignee: Noven Pharmaceuticals, Inc.Inventor: Viet Nguyen
-
Patent number: 8246978Abstract: This invention relates to a transdermal drug delivery device that comprises an active ingredient (AI) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the AI layer having a perimeter that extends beyond the perimeter of the AI layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the AI layer having a perimeter of which extends beyond the perimeter of the AI layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the perimeter of the AI layer to form a seal that reduces or prevents volatile component loss.Type: GrantFiled: July 10, 2008Date of Patent: August 21, 2012Assignee: Agile Therapeutics, Inc.Inventors: Agis Kydonieus, Robert G. Conway, Thomas M. Rossi
-
Patent number: 8246977Abstract: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.Type: GrantFiled: October 21, 2005Date of Patent: August 21, 2012Assignee: Durect CorporationInventors: Su Il Yum, Felix Theeuwes
-
Patent number: 8246982Abstract: A pressure sensitive adhesive for medicinal application purposes, based on ethylene-vinyl acetate copolymers is characterized in that it contains as polymer component (A) an ethylene-vinyl acetate copolymer or a combination of at least two ethylene-vinyl acetate copolymers, and as component (B) an adhesive resin or a combination of adhesive resins at a portion of up to 55%-wt, relative to the sum of components (A) and (B) without active substances or other auxiliary substances.Type: GrantFiled: November 1, 2010Date of Patent: August 21, 2012Assignee: LTS Lohmann Therapie-Systeme AGInventors: Andreas Koch, Christoph Schmitz
-
Patent number: 8246980Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.Type: GrantFiled: July 28, 2003Date of Patent: August 21, 2012Assignee: UCB Pharma GmbHInventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
-
Patent number: 8246979Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.Type: GrantFiled: July 22, 2003Date of Patent: August 21, 2012Assignee: UCB Pharma GmbHInventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
-
Publication number: 20120207816Abstract: Provided is a donepezil-containing transdermal absorption formulation that can sustainably administer donepezil for a long period of time, and can provide both a rapid increase in the blood level of donepezil and donepezil sustained release properties. The donepezil-containing transdermal absorption formulation is a transdermal absorption formulation produced by dissolving donepezil, which is the active ingredient, in an adhesive patch base that contains a hydrophobic polymer and an absorption promoter. The absorption promoter is one kind or two or more kinds selected from lauryl alcohol, triethyl citrate, isopropyl myristate, cetyl lactate, oleyl alcohol, sorbitan monooleate, polyethylene glycol monostearate, lauromacrogol, N-methyl-2-pyrrolidone, and triacetin.Type: ApplicationFiled: October 18, 2010Publication date: August 16, 2012Applicant: Teikiky Seiyaku Co., Ltd.Inventors: Satoshi Kawakami, Masahiro Yamaji
-
Patent number: 8241662Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.Type: GrantFiled: December 21, 2006Date of Patent: August 14, 2012Assignee: Watson Laboratories, Inc.Inventors: Charles D. Ebert, Steven W. Sanders
-
Patent number: 8237010Abstract: A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof. In use, the surface having the depressions is disposed adjacent a surface of the wound. A method of manufacturing a therapeutic device for promoting the healing of a wound in a mammal comprising the steps of providing a permeable substrate, and forming a plurality of depressions into a surface of the permeable substrate to provide the therapeutic device. A method of treating a wound comprises: providing a permeable structure comprising a plurality of randomly disposed fibers and having i) a plurality of wound surface contact elements disposed between end portions of the structure, and ii) a plurality of voids defined by the contact elements; and applying the permeable structure to at least one surface of the wound.Type: GrantFiled: August 30, 2011Date of Patent: August 7, 2012Assignee: Boehringer Technologies, L.P.Inventors: John R. Boehringer, John Karpowicz, Christopher L. Radl
-
Patent number: 8231906Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.Type: GrantFiled: July 10, 2008Date of Patent: July 31, 2012Assignee: Noven Pharmaceuticals, Inc.Inventor: Juan Mantelle
-
Patent number: 8227656Abstract: A wound treatment-dressing is shown which includes a dressing body formed from a medically inert, moisture permeable, urethane open-cell foam which is hydrophilic in nature. The foam body has a foam matrix of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobials as active agents, the active agents being incorporated into the foam matrix both topically on a foam cell surface and integrally within the foam cell wall. The antimicrobials are manufactured in a selected particle size range which improves predictability and performance of the wound dressing.Type: GrantFiled: February 5, 2010Date of Patent: July 24, 2012Inventor: Harvey E. Svetlik
-
Patent number: 8226974Abstract: The invention relates to transdermal therapeutic systems which have the active ingredient nicotine and have particularly high flexibility. This flexibility decisively improves wearer comfort on the skin, since the system is readily capable of adapting to the surface of the skin and its constant movement. Surprisingly, the nicotine TTS of the invention is markedly more flexible than the conventional nicotine TTS products which are leaders in the market, although at least some of those systems are comparably thin.Type: GrantFiled: February 19, 2002Date of Patent: July 24, 2012Assignee: LTS Lohmann Therapie-Systeme AGInventors: Stefan Bracht, Sabine Warnus